Biomm (BIOM3) Stock Overview
Operates as a biotechnology company in Brazil. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BIOM3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Biomm S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$7.00 |
| 52 Week High | R$10.73 |
| 52 Week Low | R$6.15 |
| Beta | 0.96 |
| 1 Month Change | -6.79% |
| 3 Month Change | -30.83% |
| 1 Year Change | -25.53% |
| 3 Year Change | 13.82% |
| 5 Year Change | -56.11% |
| Change since IPO | 900.00% |
Recent News & Updates
Lacklustre Performance Is Driving Biomm S.A.'s (BVMF:BIOM3) 25% Price Drop
Jan 04
Revenues Working Against Biomm S.A.'s (BVMF:BIOM3) Share Price Following 27% Dive
Nov 07Biomm (BVMF:BIOM3) Is Carrying A Fair Bit Of Debt
Oct 29Recent updates
Lacklustre Performance Is Driving Biomm S.A.'s (BVMF:BIOM3) 25% Price Drop
Jan 04Revenues Working Against Biomm S.A.'s (BVMF:BIOM3) Share Price Following 27% Dive
Nov 07Biomm (BVMF:BIOM3) Is Carrying A Fair Bit Of Debt
Oct 29Biomm S.A.'s (BVMF:BIOM3) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Sep 19Biomm S.A. (BVMF:BIOM3) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Jun 13Subdued Growth No Barrier To Biomm S.A. (BVMF:BIOM3) With Shares Advancing 31%
Dec 31Is Biomm (BVMF:BIOM3) Using Too Much Debt?
Dec 25Biomm S.A. (BVMF:BIOM3) Investors Are Less Pessimistic Than Expected
Jul 05Is Biomm (BVMF:BIOM3) Weighed On By Its Debt Load?
May 24Biomm S.A.'s (BVMF:BIOM3) 69% Price Boost Is Out Of Tune With Revenues
Apr 18Biomm S.A.'s (BVMF:BIOM3) Share Price Is Matching Sentiment Around Its Revenues
Feb 21Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt
Nov 12We Think Biomm (BVMF:BIOM3) Has A Fair Chunk Of Debt
Jul 25Positive Sentiment Still Eludes Biomm S.A. (BVMF:BIOM3) Following 26% Share Price Slump
Apr 17Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt
Feb 28Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt
Oct 15Biomm (BVMF:BIOM3) Is Carrying A Fair Bit Of Debt
Jun 29We Think Biomm (BVMF:BIOM3) Has A Fair Chunk Of Debt
Aug 17Here's Why Biomm (BVMF:BIOM3) Can Afford Some Debt
Apr 05Biomm (BVMF:BIOM3) Shareholders Have Enjoyed An Impressive 173% Share Price Gain
Mar 01Do Institutions Own Biomm S.A. (BVMF:BIOM3) Shares?
Jan 25Is Biomm (BVMF:BIOM3) A Risky Investment?
Dec 21Shareholder Returns
| BIOM3 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -1.7% | -0.6% | 1.3% |
| 1Y | -25.5% | 26.0% | 20.4% |
Return vs Industry: BIOM3 underperformed the BR Biotechs industry which returned 26% over the past year.
Return vs Market: BIOM3 underperformed the BR Market which returned 20.4% over the past year.
Price Volatility
| BIOM3 volatility | |
|---|---|
| BIOM3 Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 1.6% |
Stable Share Price: BIOM3's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: BIOM3's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Heraldo Marchezini | www.biomm.com |
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and in cases of acute myocardial infarction; and RANIVISIO for the treatment of vision problems related to abnormal blood vessel growth or fluid buildup in the retina.
Biomm S.A. Fundamentals Summary
| BIOM3 fundamental statistics | |
|---|---|
| Market cap | R$957.89m |
| Earnings (TTM) | -R$61.66m |
| Revenue (TTM) | R$142.53m |
Is BIOM3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOM3 income statement (TTM) | |
|---|---|
| Revenue | R$142.53m |
| Cost of Revenue | R$119.75m |
| Gross Profit | R$22.78m |
| Other Expenses | R$84.44m |
| Earnings | -R$61.66m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
May 15, 2026
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 15.98% |
| Net Profit Margin | -43.26% |
| Debt/Equity Ratio | 35.8% |
How did BIOM3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/15 00:52 |
| End of Day Share Price | 2026/01/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biomm S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.